News for Healthier Living

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated long-term follow-up data from the pivotal study of PAPZIMEOS(tm) (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).

June 1, 2026


June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026

May 20 2026

May 19 2026